Atlas Arteria Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Atlas Arteria wird ein jährliches Gewinn- und Umsatzwachstum von 14.6% bzw. 18.9% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 13.6% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 8.5% betragen.

Wichtige Informationen

14.6%

Wachstumsrate der Gewinne

13.6%

EPS-Wachstumsrate

Infrastructure Gewinnwachstum	20.8%
Wachstumsrate der Einnahmen	18.9%
Zukünftige Eigenkapitalrendite	8.4%
Analystenabdeckung	Good
Zuletzt aktualisiert	14 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Is Now An Opportune Moment To Examine Atlas Arteria Limited (ASX:ALX)?

Apr 07

What Does Atlas Arteria Limited's (ASX:ALX) Share Price Indicate?

Dec 22

Is There An Opportunity With Atlas Arteria Limited's (ASX:ALX) 43% Undervaluation?

Aug 10

Is Atlas Arteria (ASX:ALX) Using Too Much Debt?

May 31

Is There An Opportunity With Atlas Arteria Limited's (ASX:ALX) 48% Undervaluation?

Apr 14

Debra Goodin Is The Independent Chairman of the Board of Atlas Arteria Limited (ASX:ALX) And They Just Picked Up 54% More Shares

Mar 03

Here's Why Atlas Arteria (ASX:ALX) Can Afford Some Debt

Feb 27

Atlas Arteria (ASX:ALX) Has Compensated Shareholders With A Respectable 78% Return On Their Investment

Jan 31

Atlas Arteria Limited (ASX:ALX) Shares Could Be 44% Below Their Intrinsic Value Estimate

Dec 27

How Many Atlas Arteria Limited (ASX:ALX) Shares Do Institutions Own?

Dec 06

Is There Now An Opportunity In Atlas Arteria Limited (ASX:ALX)?

Nov 19

Atlas Arteria (ASX:ALX) Has Gifted Shareholders With A Fantastic 142% Total Return On Their Investment

Jul 30

Gewinn- und Umsatzwachstumsprognosen

ASX:ALX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (AUD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	260	547	765	585	4
12/31/2025	276	517	604	490	6
12/31/2024	257	523	585	368	6
12/31/2023	134	324	84	85	N/A
9/30/2023	131	315	86	87	N/A
6/30/2023	150	307	89	90	N/A
3/31/2023	145	287	81	82	N/A
12/31/2022	118	267	73	74	N/A
9/30/2022	115	264	65	66	N/A
6/30/2022	111	260	56	58	N/A
3/31/2022	106	222	51	53	N/A
12/31/2021	101	183	46	48	N/A
9/30/2021	96	134	37	41	N/A
6/30/2021	91	85	29	35	N/A
3/31/2021	99	13	29	37	N/A
12/31/2020	107	-60	29	39	N/A
9/30/2020	128	-37	40	52	N/A
6/30/2020	149	-14	52	64	N/A
3/31/2020	162	2	56	70	N/A
12/31/2019	175	17	61	76	N/A
9/30/2019	167	17	43	56	N/A
6/30/2019	159	18	25	35	N/A
3/31/2019	146	47	24	29	N/A
12/31/2018	132	77	22	23	N/A
9/30/2018	126	78	34	34	N/A
6/30/2018	120	78	45	46	N/A
3/31/2018	101	270	31	32	N/A
12/31/2017	83	462	18	18	N/A
9/30/2017	54	506	N/A	-4	N/A
6/30/2017	25	550	N/A	-25	N/A
3/31/2017	14	388	N/A	-20	N/A
12/31/2016	3	225	N/A	-16	N/A
9/30/2016	2	162	N/A	-14	N/A
6/30/2016	2	99	N/A	-13	N/A
3/31/2016	2	92	N/A	-27	N/A
12/31/2015	2	85	N/A	-42	N/A
9/30/2015	3	71	N/A	-41	N/A
6/30/2015	3	58	N/A	-40	N/A
3/31/2015	2	4	N/A	-32	N/A
12/31/2014	2	-51	N/A	-25	N/A
6/30/2014	2	-47	N/A	-25	N/A
3/31/2014	1	-3	N/A	-7	N/A
12/31/2013	1	42	N/A	11	N/A
6/30/2013	0	5	N/A	41	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ALXDas prognostizierte Gewinnwachstum (14.6% pro Jahr) liegt über der Sparquote (2.3%).

Ertrag vs. Markt: ALXDie Erträge des Unternehmens (14.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Australian (13.6% pro Jahr).

Hohe Wachstumserträge: ALXDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: ALXDie Einnahmen des Unternehmens (18.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Australian (4.9% pro Jahr).

Hohe Wachstumseinnahmen: ALXDie Einnahmen des Unternehmens (18.9% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: ALXDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (8.5 %).

Atlas Arteria Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 15%

Consensus revenue estimates increase by 10%

Price target decreased to AU$6.96

Consensus EPS estimates fall by 14%

Price target increased to AU$7.40

Recent updates

Atlas Arteria Limited to Report First Half, 2025 Results on Aug 28, 2025

Final dividend of AU$0.20 announced

Atlas Arteria Limited Announces the Retirement of Graeme Bevans as CEO and Managing Director

Atlas Arteria Limited Announces Distribution for the Six Months Ended 31 December 2023, Payable on 8 April 2024

Atlas Arteria Limited, Annual General Meeting, May 15, 2024

Atlas Arteria Limited, Annual General Meeting, May 16, 2024

Full year 2023 earnings released: EPS: AU$0.22 (vs AU$0.25 in FY 2022)

Atlas Arteria Appoints Laura Hendricks to the Board as an Independent Non-Executive Director

Atlas Arteria Limited Announces Distribution for the Six Months Ended 30 June 2023, Estimated Payment Date Is 5 October 2023

Atlas Arteria Limited Announces Distribution for the Six Months Ended 30 June 2023, Payable on 5 October 2023

Consensus EPS estimates fall by 11%

First half 2023 earnings released: EPS: AU$0.12 (vs AU$0.13 in 1H 2022)

Atlas Arteria Limited Reaffirms Distribution Guidance for the First Half and Second Half of 2023

Atlas Arteria Limited to Report First Half, 2024 Results on Aug 29, 2024

Atlas Arteria Limited Appoints Ken Daley as Director

Atlas Arteria Limited Announces Caroline Foulger Will Retire as A Director, with Effect from 1 July 2023

Consensus EPS estimates fall by 15%

Full year 2022 earnings released: EPS: AU$0.25 (vs AU$0.19 in FY 2021)

Insufficient new directors

Atlas Arteria Limited Announces Board Changes

Atlas Arteria Limited (ASX:ALX) completed the acquisition of 66.67% stake in Skyway Concession Company, LLC from CPP Investments and OMERS Infrastructure.

Now 20% undervalued after recent price drop

Atlas Arteria Limited, Annual General Meeting, Apr 27, 2023

Consensus revenue estimates increase by 10%

Atlas Arteria Limited to Report Q4, 2022 Results on Feb 23, 2023

Price target decreased to AU$6.96

Investor sentiment deteriorated over the past week

Atlas Arteria Limited Provides Distribution Guidance for the Year 2023

Atlas Arteria Limited (ASX:ALX) entered into an agreement to acquire a 66.67% stake in Skyway Concession Company, LLC for $2 billion.

Consensus EPS estimates fall by 14%

First half 2022 earnings released: EPS: AU$0 (vs AU$0.074 in 1H 2021)

Atlas Arteria Limited Provides Dividend Guidance for the First Half of 2022

Price target increased to AU$7.40

Investor sentiment improved over the past week

Atlas Arteria Limited Announces Executive Changes

Is Now An Opportune Moment To Examine Atlas Arteria Limited (ASX:ALX)?

Independent Non-Executive Director recently bought AU$76k worth of stock

Full year 2021 earnings: EPS and revenues miss analyst expectations

What Does Atlas Arteria Limited's (ASX:ALX) Share Price Indicate?

Insider recently bought AU$67k worth of stock

First half 2021 earnings released: EPS AU$0.074 (vs AU$0.14 loss in 1H 2020)

Is There An Opportunity With Atlas Arteria Limited's (ASX:ALX) 43% Undervaluation?

Is Atlas Arteria (ASX:ALX) Using Too Much Debt?

Price target decreased to AU$6.21

Is There An Opportunity With Atlas Arteria Limited's (ASX:ALX) 48% Undervaluation?

Debra Goodin Is The Independent Chairman of the Board of Atlas Arteria Limited (ASX:ALX) And They Just Picked Up 54% More Shares

Independent Chairman of the Board recently bought AU$100k worth of stock

Here's Why Atlas Arteria (ASX:ALX) Can Afford Some Debt

Full year 2020 earnings released: AU$0.061 loss per share (vs AU$0.024 profit in FY 2019)

Atlas Arteria Limited Announces Board Changes

New 90-day low: AU$5.97

Atlas Arteria Limited to Report Fiscal Year 2020 Results on Feb 25, 2021

Atlas Arteria (ASX:ALX) Has Compensated Shareholders With A Respectable 78% Return On Their Investment

Atlas Arteria Limited, Annual General Meeting, Apr 27, 2021

Atlas Arteria Limited (ASX:ALX) Shares Could Be 44% Below Their Intrinsic Value Estimate

How Many Atlas Arteria Limited (ASX:ALX) Shares Do Institutions Own?

Is There Now An Opportunity In Atlas Arteria Limited (ASX:ALX)?

Atlas Arteria Limited Announces Changes to its Board

New 90-day low: AU$5.95

New 90-day low: AU$6.07

New 90-day low - AU$6.10

Atlas Arteria Limited (ASX:ALX) acquired 6.14% stake in APRR and ADALEC from Macquarie European Infrastructure Fund II managed by Macquarie Infrastructure and Real Assets (Europe) Limited.

Earnings released

Atlas Arteria (ASX:ALX) Has Gifted Shareholders With A Fantastic 142% Total Return On Their Investment

Atlas Arteria Limited has completed a Follow-on Equity Offering in the amount of AUD 74.999999 million.

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite